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Edited by Richard MaraisAbstract The interaction of the chemokine receptor, CCR5,
expressed in recombinant cells, with diﬀerent G proteins was
investigated and CCR5 was found to interact with Gi, Go and Gq
species. Interaction with Gi leads to G protein activation,
whereas Gq does not seem to be activated. Additionally, CCR5
activation also leads to phosphorylation of Janus kinase 2
(JAK2). Activation of JAK2 is independent of Gi or Gq
activation. Gi protein activation was not prevented by inhibition
of JAK, showing that heterotrimeric G protein activation and
activation of the JAK/signal transducer and activator of
transcription (STAT) pathway are independent of each other.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The chemokine receptor, CCR5, belongs to the superfamily
of G protein coupled receptors (GPCRs) and activation of
CCR5 by chemokines has been reported to lead to changes in a
number of cellular processes, e.g., activation of G proteins [1],
increases in intracellular calcium ion concentration [2–7], in-
hibition of adenylyl cyclase [1], activation of MAP kinase [8–
10] and Jun-N-terminal Kinase (JNK) [9]. These processes are
typical of responses dependent on activation of pertussis toxin
(PTX)-sensitive G proteins of the Gi/Go family, being related
to eﬀects of either a or bc subunits of these G proteins.
Many cytokine receptors and growth factor receptors me-
diate their eﬀects by activation of a common signal transduc-
tion pathway, the STAT pathway [11,12]. Binding of the
ligand to its speciﬁc transmembrane receptor results in the
catalytic activation of receptor-associated cytoplasmic pro-* Corresponding author.
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lation-activation of latent monomeric STAT proteins [13–15].
There is now emerging evidence that GPCRs are also capable
of activating these JAK/STAT signalling pathways. A report
by Marrero et al. showed for the ﬁrst time that the JAK/STAT
pathway can be stimulated by angiotensin II via its speciﬁc
GPCR (AT1) [16]. Recently, it has been shown that GPCRs
are able to activate kinases independent of G protein activa-
tion [17–19]. Activation of some STAT transcription factor
family members has been described in T cells after CCL5 or
CCL3 stimulation which may be associated with CCR5 [20]. In
PM1 T cells CCL5 leads to phosphorylation of JAK2 and
JAK3 [21]. This phosphorylation is PTX insensitive, indicating
that CCL5-CCR5 mediated tyrosine phosphorylation events
are not mediated via Gi/Go proteins [21]. It has also been
suggested that JAK activation is necessary for receptor and
Gai proteins to associate and induce signalling [17].
It seems, therefore, that the activationof someGPCRs, including
CCR5, leads to activation of at least two intracellular signalling
systems, those dependent on heterotrimeric G proteins and those
dependent on JAK/STAT proteins. In this study, therefore, we
have examined the activation of these two systems for CCR5.2. Materials and methods
Cells and materials. Chinese hamster ovary cells (CHO cells) stably
expressing CCR5 (CHO.CCR5) or CCR5 and CD4 (CHO.CCR5.CD4)
have been described previously [22,23]. HEK.CCR5 cells were a gener-
ous gift from British Biotech (Oxford, UK) and were grown in DMEM
with 10% foetal calf serum (FCS) and 2mMglutamine in the presence of
hygromycin. THP-1 cells were from the MRC Aids Repository Pro-
gramme (Potters Bar, UK). The CCL3 isoform used is the CCL3 D26A
form and has been described in [24] and was a generous gift from British
Biotech (Oxford, UK). Anti CCR5 antibodies HEK/1/85a/7a and anti
CD4 antibodies have been described previously [22,23]. The following
anti-G protein antibodies were used: antibody C-10 (Santa Cruz) (rec-
ognises Gi1, Gi2, Gi3), anti Gq (E-17) (SantaCruz), anti Go (MAB3073),
anti-Gi2 (MAB3077) (Chemicon), and antiGi3 (SA-129) (Biomol).Anti-
phosphotyrosine antibody (PY99) and anti-JAK2 antibodies were
obtained from Santa Cruz. Anti-phospho-STAT1 and anti-STAT1 an-
tibodies were purchased from New England Biolabs. The JAK2 inhibi-
tor AG490 and the phospholipase C inhibitor U73122 (Calbiochem)
were used at 100 and 5 lM, respectively, for 1 h before an experiment.
[35S]GTPcS (37–55 TBqmmol1) was from Amersham Pharmacia. All
other chemicals were from Sigma.
Immunoprecipitation, SDS–PAGE and Western blot. Cells were har-
vested and then resuspended in lysis buﬀer (1% Brij97, 5 mM iodoacet-
amide, added immediately before use, 150 mM NaCl, 20 mM Tris (pH
8.2), 20 mM EDTA, phosphatase inhibitor cocktail (Sigma) and prote-
ase inhibitors cocktail (Roche)) at 4 C for 40 min with gentle mixing.
The immunoprecipitation and analysis of the proteins on SDS–PAGEblished by Elsevier B.V. All rights reserved.
Fig. 1. Detection of G protein expression in CHO.CCR5 cells using
ﬂow cytometry analysis and Western blot. CHO.CCR5 cells were
permeabilised and stained with unspeciﬁc antibody (thin line) or anti-
G protein antibody (bold line) and analysed by ﬂow cytometry. Inset:
for Western blots 20 lg of membranes was separated on a SDS–
PAGE. Gi and Gq were detected on a Western blot using speciﬁc
antibodies. For detection of Go, cells were subjected to an immuno-
precipitation with an anti Go antibody and Go was detected on a
Western blot using a speciﬁc antibody. Arrows indicate G protein. (a)
Detection of Gai with antibody selective for Gi1, Gi2, and Gi3, (b) Gai2,
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brane before a second stain by incubation with 100 mM mercap-
toethanol, 2% SDS, and 62.5mMTris–HCl, pH 6.8, at 50 C for 30min.
Pertussis toxin treatment. Pertussis toxin (PTX) (Sigma) was used to
uncouple the G proteins from the receptor at 100 ng/ml PTX for 2 h
before immunoprecipitation and for 18 h before calcium assays. For
[35S]GTPcS binding assays, cells were treated with PTX overnight
before the membranes were prepared.
Analysis of intracellular calcium ion concentration. Chemokine-in-
duced intracellular calcium mobilisation was determined by spectro-
ﬂuorometry as described previously [22].
Internalisation assay and ﬂow cytometry analysis. Internalisation and
recycling assays were performed as described [23]. Where an inhibitor
such as AG490 was used in the experiments, it was present in the three
sets of cells used, i.e., negative control, treated with medium without
serum and chemokine-treated. G protein levels were quantiﬁed using a
buﬀer containing 1% saponin to permeabilise cell membranes followed
by ﬂow cytometry using speciﬁc antibodies.
Membrane preparation. Membranes were prepared from conﬂuent
cells as described previously [22].
[35S]GTPcS-binding assays. The [35S]GTPcS-binding assays were
carried out essentially as described in [25]. 30 lg cell membranes were
incubated in [35S]GTPcS-binding buﬀer containing 20 mM HEPES,
100 mM NaCl, 10 mM MgCl2 and 0.1% BSA, pH 7.4, and 10 lM
GDP in a ﬁnal volume of 0.9 ml in the absence or presence of an
agonist (50 nM) to measure the basal and stimulated nucleotide ex-
change, respectively. The reaction was initiated by the addition of cell
membranes and the tubes were incubated at 30 C for 30 min before
addition of 100 ll of [35S]GTPcS to give a ﬁnal [35S]GTPcS concen-
tration of 100 pM. The assay was incubated for a further 30 min before
termination by rapid ﬁltration through GF/C ﬁlters and bound ra-
dioactivity was determined by liquid scintillation counting. Alterna-
tively, the assay was terminated by collecting the membranes by
centrifugation (10 000 g) and cooling them to 4 C. The membranes
were then resuspended in ice cold lysis buﬀer and incubated with the
corresponding antibodies for 1 h at 4 C. The antibodies had been pre-
coupled to Protein G–Sepharose (PGS) overnight. Samples were wa-
shed ﬁve times in ice-cold lysis buﬀer and bound radioactivity was
determined by liquid scintillation counting.
Data analysis. Data were analysed using GraphPad Prism (Graph-
Pad Software, San Diego, CA). Statistical analysis was performed
using Student’s t test with a P < 0:05.(c) Gao and (d) Gaq. In (c) the upper band is the heavy chain of IgG.3. Results
3.1. CCR5 interaction with G proteins
Using ﬂow cytometry it was possible to demonstrate the
presence of a-subunits of Go, Gq and Gi2 proteins inFig. 2. CCR5 co-precipitates with Gi and Gq. CHO.CCR5 cells were lysed an
antibodies was performed. (a) Interaction with Gi: Lane 1 shows co-immunop
control immunoprecipitation with antibody unrelated to G proteins and CCR
was stripped and re-probed with antibody speciﬁc for Gi1/Gi2/Gi3. (c) Interact
unrelated to G proteins and CCR5. Lane 2 shows immunoprecipitation wit
antibody. Blots shown are representatives of three independent experiments.CHO.CCR5 cells using speciﬁc antibodies (Fig. 1). Expression
of the same Gq and Gi2 G protein subunits could also be
demonstrated using the antibodies in Western blots on cell
membranes or using immunoprecipitation (Fig. 1). Go ex-
pression was very low and could only be detected afterd an immunoprecipitation with G protein speciﬁc antibodies or control
recipitation with antibody speciﬁc for Gi1, Gi2, and Gi3. Lane 2 shows
5 Western blot was performed with anti CCR5 antibody. (b) Blot in a
ion with Gq: Lane 1 shows control immunoprecipitation with antibody
h Gq speciﬁc antibody. Western blot was performed with anti CCR5
Fig. 3. Activation of G proteins by chemokines via CCR5. [35S]GTPcS
binding was determined after 30 min incubation in the presence or
absence of 50 nM CCL3. G proteins were precipitated using speciﬁc
antibodies and [35S]GTPc S binding determined as described in Section
2. Results are expressed as a percentage of the unstimulated basal level
of [35S]GTPcS binding. Data shown are the means and standard errors
of at least three separate experiments. (a) shows immunoprecipitation
with antibodies speciﬁc for diﬀerent G proteins (***P < 0:001,
**P < 0:01), control experiments were performed with PGS alone. (b)
shows immunoprecipitation without antibody or with Gi and Gq
speciﬁc antibodies for membranes with or without PTX treatment. As
a negative control immunoprecipitation with PGS was performed. (c)
Intracellular calcium ion concentration was determined as described
with CCL3 (50 nM). Data are shown with control cells and cells
treated with PTX (100 ng/ml, 18 h).
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Western blotting. Immunoreactivity in ﬂow cytometry and
Western blotting was also seen with an antibody that cross
reacts with Gi1, Gi2 and Gi3. Gi3 could be detected at low levels
in Western blots (data not shown), but the antibodies used
were unsuitable for immunoprecipitation. These data are in
agreement with previous studies [26,27] where it was shown
that CHO cells express Gi2 and Gi3 (in smaller amounts) but
only low levels of Gi1 and Go. In several experiments described
below, the antibody that cross-reacts with Gi1, Gi2 and Gi3 has
been used. Immunoreactivity detected with this antibody will
be referred to as Gi, but we may assume that it is largely Gi2
that is being assessed.
We then investigated the association of CCR5 with diﬀerent
G proteins. Co-immunoprecipitation studies revealed that
CCR5 associates with Gi, Go and also Gq (Fig. 2). Owing to
the low amount of Go in CHO cells, only a very faint CCR5-
speciﬁc band was observed in the co-precipitation experiments
(data not shown).
CCR5, therefore, interacts with several members of the G
protein family in CHO cells. In order to determine if these in-
teractions are functional, we performed a [35S]GTPcS binding
assay followed by immunoprecipitation with speciﬁc anti G
protein antibodies. This approach has been used to demon-
strate functional interaction between muscarinic acetylcholine
receptors and Gi/Go/Gq proteins and between Edg receptors
and Gi/Go proteins [28,29]. Application of this technique
showed that CCR5 is able to activate Gi proteins as bound
[35S]GTPcS was detected following immunoprecipitation with
antibodies speciﬁc for Gi1-3 and Gi2 species after stimulation
with CCL3 (Fig. 3(a)). However, we did not observe a speciﬁc
activation of Gq or Go proteins in this assay. The stimulation of
Gi proteins was prevented by PTX treatment (Fig. 3(b)). In
complementary experiments, PTX treatment completely abol-
ished the CCL3-induced increase in intracellular calcium ions
showing that the interaction of CCR5 with Gi proteins is
functionally relevant (Fig. 3(b)). Further evidence that the in-
teraction of CCR5 with Gi proteins is functionally relevant
comes from the observation that chemokine-induced inter-
nalisation of CCR5 is sensitive to PTX treatment implying a
role for CCR5/Gi interaction in the internalisation process [23].
3.2. CCR5 interaction with JAK2
CHO.CCR5 cells were treated with CCL3 and proteins ex-
hibiting enhanced tyrosine phosphorylation were detected us-
ing immunoprecipitation with an antibody directed against
phosphotyrosine residues. The phosphorylation of one of the
bands was prevented by AG490, a JAK1/JAK2 inhibitor [30]
(Fig. 4(a)), whereas a phospholipase C inhibitor U73122 had
no eﬀect on the amount of phosphorylation after CCR5 acti-
vation. We suspected that this band might be JAK2 as other
GPCRs have been reported to alter JAK2 phosphorylation
[16,21,32]. We were unable to prove this as the available JAK2
antibody was speciﬁc for the human protein and did not react
with CHO cell JAK2 (data not shown).
The experiments were, therefore, repeated using a HEK cell
line expressing CCR5. Treatment of the HEK.CCR5 cells with
CCL3 leads to enhanced tyrosine phosphorylation of proteins
in these cells and this was prevented by AG490 (Fig. 4(b)) in
agreement with the data obtained in CHO.CCR5 cells. In or-
der to examine the role of JAK2 in these observations, we
performed an immunoprecipitation with an anti-JAK2 anti-body followed by a Western blot probed with an anti-phos-
photyrosine antibody. These experiments showed that JAK2
phosphorylation was enhanced by CCL3 activation of CCR5
and this occurred in a transient manner, reaching a peak after
1 min and returning to baseline by 15 min (Fig. 5(a)). Treat-
ment of cells overnight with PTX or for 1 h with U73122 did
not aﬀect the amount of phosphotyrosine phosphorylation
that was observed, indicating that JAK2 activation is inde-
pendent of Gi=o protein activation and also independent of
phospholipase C activation (Fig. 5(b) and (c)).
Fig. 5. Transient activation of JAK2 is independent of heterotrimeric
G protein activation. (a) HEK.CCR5 cells were treated with 50 nM
CCL3 for the times indicated and then subjected to immunoprecipi-
tation with JAK2 antibody. Upper panel: Western blot analysis was
performed with an anti-phosphotyrosine antibody. Arrow indicates
JAK2, as shown in experiments with the JAK2 antibody. Lower panel:
membranes were reprobed with an anti-JAK2 antibody. Arrow indi-
cates JAK2. (b) HEK.CCR5 cells were treated with PTX (100 ng/ml)
for 18 h and treated with CCL3 (50 nM, 10 min) when indicated.
Immunoprecipitation and Western blot analysis were performed with
anti-phosphotyrosine antibody. Arrow indicates position of JAK2. (c)
HEK.CCR5 cells were treated with U73122 (5 lM) for 1 h and then
treated with CCL3 (50 nM, 10 min) when indicated and then subjected
to immunoprecipitation with an JAK2 antibody. Upper panel: Wes-
tern blot analysis was performed with an anti-phosphotyrosine anti-
body. Arrow indicates JAK2. Lower panel: membranes were reprobed
with an anti-JAK2 antibody. Arrow indicates position of JAK2.
Control Western blots are also shown identifying the position of
JAK2.
Fig. 4. Ligand-induced CCR5 activation leads to a JAK-inhibitor
dependent increase in tyrosine-phosphorylation in CHO and HEK
cells. (a) CHO.CCR5.CD4 cells were treated with AG490 (100 M) and
U73122 (5 lM) when indicated for 1 h before addition of the agonist.
Immunoprecipitation and Western blot analysis were performed with
an anti-phosphotyrosine antibody. (b) HEK.CCR5 cells were treated
with AG490 (100 lM) for 1 h before addition of CCL3. Immuno-
precipitation and Western blot analysis were performed with an anti-
phosphotyrosine antibody. Arrows indicate the staining pattern after
CCR5 activation, upper arrow corresponds to JAK2.
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for G protein activation, we examined the stimulation of
[35S]GTPcS binding induced by CCL3 in membranes of
CHO.CCR5 cells (Fig. 6(a)). This has been shown to be a re-
ﬂection of the activation of Gi=o proteins by CCR5 [22].
Stimulation of [35S]GTPcS binding by CCL3 was unaﬀected
by the presence of AG490 (100 lM) the JAK1/JAK2 inhibitor
[30]. This concentration of AG490 was suﬃcient to prevent
JAK2 phosphorylation stimulated by CCL3 (see above). In
order to investigate the eﬀects of JAK2 on G protein activation
in whole cells, we examined CCL3 stimulation of intracellular
calcium ion release. This has been shown to be a reﬂection of
activation of Gi=o proteins (Fig. 3(b)). AG490 did not aﬀect the
CCL3-induced increase in intracellular calcium ion concen-
tration (Fig. 6(b)). These data suggest that activation of JAK1
or JAK2 is not a prerequisite for the stimulation of G proteins
by CCR5 in these cells.
Since activation of CCR5 leads to activation of JAK2, we
examined whether the two proteins interacted. Immunopre-
cipitation studies clearly showed that CCR5 interacts directly
with JAK2 (Fig. 7). CCL3-induced receptor activation did not
aﬀect the interaction of JAK2 and CCR5. Similar interaction
of CCR5 and JAK2 was seen, using co-precipitation, in the
monocytic THP-1 cell line (Fig. 7), suggesting that this is not a
phenomenon restricted to recombinant systems.
In order to examine the importance of the interaction of
CCR5 and JAK2 further, we examined the eﬀect of JAK2
inhibition on CCL3-induced internalisation and recycling of
CCR5. Inhibition of JAK1/JAK2 with AG490 did not aﬀect
CCR5 internalisation, but in the two cell lines used(CHO.CCR5, CHO.CCR5.CD4), there was some inhibition of
receptor recycling to the cell surface (Fig. 8) compared to
untreated cells. This most likely reﬂects the eﬀects on JAK2,
but owing to the speciﬁcity of AG 490 we cannot rule out the
eﬀects via JAK1.
It has been shown recently that CCR5 is shed from CHO
cells into the supernatant in microvesicles [31]. In the present
Fig. 7. Co-immunoprecipitation of JAK2 with CCR5 is independent of
ligand-induced receptor activation. HEK.CCR5 cells were treated with
50 nM CCL3 for 10 min when indicated. (a) Cells were then subjected
to immunoprecipitation with an anti-CCR5 antibody, Western blot
analysis was performed with an anti-JAK2 antibody. Arrow indicates
position of JAK2 veriﬁed by control Western blot. (b) Cells were
subjected to immunoprecipitation with an anti-JAK2 antibody, Wes-
tern blot analysis was performed with an anti-CCR5 antibody. Arrow
indicates position of CCR5 veriﬁed by control Western blot. (c) Ac-
tivation of CCR5 does not lead to activation of STAT1 in HEK.CCR5
cells. HEK.CCR5 cells were activated with CCL3 and then subjected
to immunoprecipitation with an anti-phospho-STAT1 antibody,
Western blot analysis was performed with an anti-STAT1 antibody.
Arrow indicates position of STAT1 veriﬁed by control Western blot.
(d) CCR5 and JAK2 interact in THP-1 cells. Immunoprecipitation was
performed with anti-JAK2 or anti-CCR5 antibody where indicated
and Western blot was performed with anti-CCR5 antibody. The non-
speciﬁc bands are immunoglobulins.
Fig. 6. Eﬀects of JAK inhibitor AG490 on heterotrimeric G protein
activation. (a) Stimulation of [35S]GTPcS binding in CHO.CCR5.CD4
membranes by CCL3: eﬀect of JAK inhibitor AG490. [35S]GTPcS
binding was determined after 30 min incubation in the presence of
increasing concentrations of CCL3 as described in Section 2. Where
indicated, membranes were pre-treated with 100 lM AG490 for 1 h
before determination of [35S]GTPcS binding. Data shown are the
means of triplicate determinations from a representative of at least
three separate experiments. (b) CHO.CCR5.CD4 cells were prepared
for calcium ﬂux as described and then stimulated with 100 nM CCL3.
(c) CHO.CCR5.CD4 cells were incubated with AG490 (100 lM) for
1 h and then prepared for calcium ﬂux. Cells were stimulated with
100 nM CCL3.
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cells using speciﬁc anti-CCR5 antibodies. We also detected Gi
proteins in the same supernatant (Fig. 9). It, therefore, seems
that CCR5 is coupled very tightly to Gi proteins even in the
inactive state of the receptor and the two proteins are shed
together from the cells. In the same experiments, CD4 was
found only in the fraction containing whole cells, not in the
fraction containing shed vesicular material. This shows that
the shedding of CCR5 is a speciﬁc process and is not due to cell
lysis during the experiment. It is possible that CCR5 and Gi
are being shed as part of a complex of signalling proteins. We,
therefore, repeated the experiments in HEK.CCR5 and un-
transfected HEK cells. In the supernatant of cells that were
stably transfected with CCR5 we detected CCR5 in addition toJAK2. The supernatant of the cells was passed through a 0.45
lm ﬁlter to eliminate any cells in the supernatant. Even after
ﬁltration, we were still able to detect CCR5 and JAK2 in the
supernatant. We then used parental HEK cells to investigate
whether JAK2 is leaking non-speciﬁcally from cells, or whe-
ther the shedding of the protein is dependent on the presence
of CCR5. In parental HEK cells we were unable to detect any
JAK2 in the supernatant of the cells conﬁrming the tight as-
sociation between CCR5 and signalling proteins such as JAK2
and Gi (data not shown).
Fig. 8. Internalisation and recycling of CCR5. (a) CHO.CCR5.CD4
cells were treated with CCL3 as in [23] and cell surface expression of
CCR5 was determined by ﬂow cytometry. The zero time point in the
graph represents the CCR5 level after internalisation. Cells were then
washed to remove CCL3 and recycling of CCR5 determined after dif-
ferent times as in [23]. Cells were pre-treated with AG490 where indi-
cated (100 lM) for 1 h. (b) CHO.CCR5 cells were treated as in (a). Data
represent means S.E.M. of at least three independent experiments.
Fig. 9. Detection of CCR5 and G protein in supernatant of cells ex-
pressing CCR5. (a) CHO.CCR5.CD4 cells were incubated in PBS for
15 min and then centrifuged for 10 min at 1000 g. Supernatant was
collected, diluted in 2 sample buﬀer and boiled for 5 min. Pellets were
lysed using an ultra-turrax, then 2 sample buﬀer was added and the
samples were boiled for 5 min. Both sets of samples were then sepa-
rated on SDS–PAGE. SN is supernatant, P is pellet fraction. (b)
HEK.CCR5 cells were treated as described in (a). SN is supernatant, F
is supernatant fraction after ﬁltration through 0.45 lm ﬁlter. Western
blot analyses were performed with antibodies speciﬁc for CCR5, CD4,
G proteins or JAK2 as indicated.
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In this study, we examined the eﬀects of stimulation of the
chemokine receptor, CCR5, on two signalling systems, het-
erotrimeric G proteins and JAK/STAT proteins. We provide
the ﬁrst evidence that CCR5 can couple independently to G
protein-coupled and non-G protein-coupled pathways.
Recently, evidence has emerged that the JAK/STAT path-
ways may be activated by GPCRs, e.g., angiotensin AT1 re-
ceptor [16], a1-adrenergic receptors [32], and CCR5 [21,33,34].
Interaction of JAK2 with CCR5 after activation with CCL5
has also been described [21]. These eﬀects of GPCRs on JAK/
STAT pathways raise questions about how one receptor can
signal to multiple signalling pathways. In the case of CCR5, it
has even been suggested that activation of heterotrimeric G
proteins is dependent on JAK activation [19].
In this study, therefore, we have investigated the activation
of diﬀerent signalling pathways linked to CCR5 using re-
combinant cells expressing CCR5. Activation of CCR5 byCCL3 leads to activation of the G protein Gi2 as shown by
increased [35S]GTPcS binding. CCL3 activation of CCR5 also
leads to activation of JAK2 as shown by increased tyrosine
phosphorylation. The two signalling events are independent, as
inhibition of one event (PTX to inhibit Gi proteins AG490 to
inhibit JAK2) has no eﬀect on the other event. Co-immuno-
precipitation studies showed that CCR5 interacted with the
two signalling proteins (Gi and JAK2) in support of these
observations. Additionally, use of the phospholipase C inhib-
itor, U73122, showed that JAK2 activation by CCR5 was not
dependent on activation of phospholipase C. This also elimi-
nates the eﬀects of CCR5 via Gq proteins. Although we did
observe activation of JAK2 in our system, we were not able to
detect any downstream activation of STAT 1 following acti-
vation of CCR5 (Fig. 7). Other downstream eﬀectors of JAK2
(see [35] for review) must, therefore, be involved in these
responses.
Recently, Mack et al. [31] reported that CCR5 is shed from
cells into the supernatant without lysis of the cells. This process
may be involved in movement of CCR5 from one cell to an-
other. CCR5 has also been shown to be located on microvilli,
an observation that strengthens the possibility of shedding the
receptor in microvesicles from cells [36]. We used these ob-
servations to examine the interaction of CCR5 with signalling
proteins. Both CCR5 and Gi proteins could be detected in the
supernatant of CHO.CCR5.CD4 cells, whereas CD4 was not
found in the supernatant. In HEK.CCR5 cells, we could detect
JAK2 together with CCR5 in the supernatant, whereas in
parental HEK cells, no JAK2 could be detected in the super-
natant. This suggests that G proteins and JAK2 are either
tightly associated with the receptor even in an inactive state, so
that they are shed from the cells together with CCR5 or that
these proteins are in close proximity to CCR5, when the re-
ceptor is shed in microvesicles. Whether this phenomenon is of
physiological importance remains to be clariﬁed. It does,
132 A. Mueller, P.G. Strange / FEBS Letters 570 (2004) 126–132however, strengthen the theory that both G proteins and JAK2
are directly associated with CCR5.
This study therefore shows that CCR5 is able to activate Gi
proteins as well as JAK2 proteins in an independent manner,
providing new insights into the complex signalling pathways
that are activated by CCR5. Thus, as well as having short term
eﬀects on cell activity via changes in G protein activation,
CCR5 may lead to changes in cell growth via alterations in
JAK activity [35].
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